[1] 中华医学会消化病学分会.中国肝硬化临床诊治共识意见[J].临床肝胆病杂志,2023,39(9):2057-2073.
[2] GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet,2018,392(10159):1736-1788.
[3] 中华中医病学会肝胆病学分会.肝硬化中医诊疗指南[J].临床肝胆病杂志,2024,40(3):461-472.
[4] Baveno Ⅶ Faculty.Baveno Ⅶ-renewing consensus in portal hypertension[J].J Hepatol, 2022,76(4):959-974.
[5] Liu YQ, Zhang C, Li JW, et al. An-Luo-Hua-Xian pill improves the regression of liver fibrosis in chronic hepatitis B patients treated with entecavir[J].J Clin Transl Hepatol,2023,11(2):304-313.
[6] Xiao HM, Shi MJ, Jiang JM, et al. Efficacy and safety of AnluoHuaxian pills on chronic hepatitis B with normal or minimally elevated alanine transaminase and early liver fibrosis: a randomized controlled trial[J].J Ethnopharmacol,2022,293:115210.
[7] Guanghua R, Yongping C, Zujiang Y, et al.Synergistic effect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir:a multicenter, randomized, double-blind, placebo-controlled trial[J].J Infect Dis,2020(6):6.
[8] Hassanein T, Tai D, Liu C, et al. Efficacy and safety of a botanical formula Fuzheng Huayu for hepatic fibrosis in patients with CHC: results of a phase 2 clinical trial[J].Evid Based Complement Alternat Med,2022:4494099.
[9] Zhao ZM, Zhu CW, Huang JQ, et al. Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment:a single arm clinical objective performance criteria trial[J].J Ethnopharmacol,2022,298:115599.
[10]Gao YQ, Zhang X, Li M, et al. Bushenjianpi formula combined with entecavir for HBeAg-negative chronic hepatitis B patients: a multicentre, randomised, double-blind, placebo-controlled trial[J].Lancet,2016,388:S33.
[11]Zhu XJ, Sun XH, Zhou ZH, et al. Lingmao formula combined with entecavir for HBeAg-positive chronic hepatitis B patients with mildly elevated alanine aminotransferase: a multicenter, randomized, eouble-blind, placebo-controlled trial[J].Evid Based Complement Alternat Med,2013,2013:620230.
[12]施梅姐,萧焕明,谢玉宝,等.中医药防治慢性乙型肝炎肝纤维化的现状、挑战与思考[J].临床肝胆病杂志,2023,39(6):1280-1286.
[13]肖定洪,顾杰,蔡虹,等.扶正化瘀胶囊预防肝硬化患者食管静脉曲张破裂出血的随机对照多中心临床研究[J].中华肝脏病杂志,2014,22(8):594-599.
[14]中华中医药学会脾胃病分会.肝硬化腹水中医诊疗专家共识意见(2017)[J].临床肝胆病杂志,2017,33(9):1621-1626.
[15]Ji D, Chen Y, Bi J, et al. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B[J].J Hepatol,2022,77(6):1515-1524.
[16]Shen B, Deng L, Liu Y, et al. Effects of novel Fufang Biejia Ruangan tablets with sheep placenta as substitute for hominis placenta on CCl₄-induced liver fibrosis[J].Chin Herb Med,2021,14(1):104-110.
[17]王林,卢玮,高玉华,等.安络化纤丸对肝纤维化大鼠肝组织基质金属蛋白酶及其抑制物表达的影响[J].中华肝脏病杂志,2019,27(4):267-273.
[18]Wang LT, Zhang B, Chen JJ. Effect of anti-fibrosis compound on collagen expression of hepatic cells in experimental liver fibrosis of rats[J].World J Gastroenterol,2000,6(6):877-880.
[19]孙学华,张鑫,周振华,等.消胀方对四氯化碳诱导大鼠肝纤维化的防治作用[J].中国实验方剂学杂志,2015,21(9):102-107.
[20]Jiang C, Iwaisako K, Cong M, et al. Traditional Chinese medicine Fuzheng Huayu prevents development of liver fibrosis in Mice[J].Arch Clin Biomed Res,2020,4(5):561-580.
[21]Horn P, Tacke F. Metabolic reprogramming in liver fibrosis[J].Cell Metab,2024,36(7):1439-1455.
[22]曾震军,李曼,孙学华,等.中药灵猫方的抗肝纤维化作用及其机制[J].中华临床医师杂志(电子版),2012,6(15):4258-4262.
[23]鲁军,周凝,黄棪,等.疏肝健脾活血方对肝星状细胞/肝窦内皮细胞共培养体系中VEGF/VEGFR表达的影响[J].中医杂志,2019,60(3):242-247.
[24]陈佳美,慕永平,刘平.“病-方(效)-证”的研究实践与创新发展(二)——一贯煎治疗肝硬化的方证病理学基础探析[J].上海中医药大学学报,2023,37(2):1-6,21.
[25]Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease[J].Nat Rev Microbiol,2023,21(11):719-733.
[26]尚小飞,李秀惠.中药抗肝纤维化实验研究进展[J].临床肝胆病杂志,2023,39(2):249-259.
[27]贾可欣,李寒,刘闰平.调和肝脾类中药治疗“肠-肝”轴相关疾病作用机制的研究进展[J].中草药,2023,54(5):1609-1619.